Study S002406

Effects of SGLT2 Inhibitors on Coronary Atherosclerosis Progression in Diabetes Mediated by Perivascular Adipose Tissue: The SCOPE Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07614230
Acronym: SCOPE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: RECRUITING
Enrollment: 144
Start: 2026-01-01
Primary completion: 2027-06-01
Lead sponsor: Junjie Yang
Conditions: Type 2 Diabetes Mellitus (T2DM); Coronary Artery Disease; Atherosclerosis
Interventions: DRUG:Dapagliflozin (DAPA); OTHER:Standard Care (Treatment as Usual)
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:82470342

Registered primary outcomes

Progression of Coronary Plaque Volume and Proportion from Baseline to the 18-Month Follow-Up [Baseline to 18 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.